This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Premier, Inc. (PINC) Tops Q4 Earnings Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.49% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
THRN vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
THRN vs. HQY: Which Stock Is the Better Value Option?
Reasons to Retain West Pharmaceutical (WST) Stock for Now
by Zacks Equity Research
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
by Zacks Equity Research
McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
by Zacks Equity Research
The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) broad product line.
3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of 340% and 5.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of 0% and 2.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Receives FDA Nod to Address Critical Infusion Needs
by Zacks Equity Research
The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Avantor's (AVTR) New Expansion Plans to Boost Workflow
by Zacks Equity Research
Avantor's (AVTR) latest expansion plans are likely to aid customers in creating customized workflow solutions.
New Strong Buy Stocks for July 20th
by Zacks Equity Research
HQY, SKFRY, AZEK, CIR and ATR have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2023.
Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease
by Zacks Equity Research
Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and McKesson (MCK) have performed compared to their sector so far this year.
Here's Why You Should Add BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Masimo's (MASI) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Masimo's (MASI) second-quarter 2023 results are likely to have been dampened by the postponement of orders and increased hospital labor costs, among others.
Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.
Thermo Fisher (TMO) Launches Diomni Enterprise Software
by Zacks Equity Research
Thermo Fisher's (TMO) Diomni Enterprise Software effortlessly connects each individual processing stage to a single, integrated platform.